Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Apr 7;8:141–153. doi: 10.2147/BTT.S37509

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 Tanaka et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License

The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Indirect comparisons of the suppressive effects of tocilizumab and tumor necrosis factor inhibitors on radiographic damage.

Notes: Copyright © 2012. Adapted from Dove Medical Press. Jones G, Darian-Smith E, Kwok M, Winzenberg T. Effect of biologic therapy on radiological progression in rheumatoid arthritis: what does it add to methotrexate? Biologics. 2012;6:155–161.³⁰ In combination with methotrexate (MTX) compared with MTX alone, tocilizumab and all tumor necrosis factor inhibitors are effective at slowing X-ray progression. As monotherapy, adalimumab, etanercept, and tocilizumab are significantly better than MTX, whereas golimumab had no significant effect. The x-axis shows progression of radiographic damage.

Abbreviations: CI, confidence interval; MTX, methotrexate.